- Home
- MGRX vs NLSP Comparison
MGRX vs NLSP Comparison
Compare MGRX & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- NLSP
- Stock Information
- Founded
- MGRX 2021
- NLSP 2015
- Country
- MGRX United States
- NLSP Switzerland
- Employees
- MGRX N/A
- NLSP N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- MGRX Technology
- NLSP Health Care
- Exchange
- MGRX Nasdaq
- NLSP Nasdaq
- Market Cap
- MGRX 12.3M
- NLSP 6.9M
- IPO Year
- MGRX 2023
- NLSP 2021
- Fundamental
- Price
- MGRX $4.04
- NLSP $1.53
- Analyst Decision
- MGRX
- NLSP
- Analyst Count
- MGRX 0
- NLSP 0
- Target Price
- MGRX N/A
- NLSP N/A
- AVG Volume (30 Days)
- MGRX 79.8K
- NLSP 108.6K
- Earning Date
- MGRX 03-31-2025
- NLSP 10-18-2024
- Dividend Yield
- MGRX N/A
- NLSP N/A
- EPS Growth
- MGRX N/A
- NLSP N/A
- EPS
- MGRX N/A
- NLSP N/A
- Revenue
- MGRX $755,000.00
- NLSP N/A
- Revenue This Year
- MGRX N/A
- NLSP N/A
- Revenue Next Year
- MGRX N/A
- NLSP N/A
- P/E Ratio
- MGRX N/A
- NLSP N/A
- Revenue Growth
- MGRX 52.20
- NLSP N/A
- 52 Week Low
- MGRX $2.07
- NLSP $1.47
- 52 Week High
- MGRX $16.80
- NLSP $18.40
- Technical
- Relative Strength Index (RSI)
- MGRX 48.24
- NLSP 35.59
- Support Level
- MGRX $3.59
- NLSP $1.57
- Resistance Level
- MGRX $5.33
- NLSP $1.68
- Average True Range (ATR)
- MGRX 0.58
- NLSP 0.12
- MACD
- MGRX -0.09
- NLSP -0.02
- Stochastic Oscillator
- MGRX 26.07
- NLSP 10.91
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.